Compare Sanofi SA (SNY) vs SpaceX (SPCX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs SpaceX — how do they compare? Sanofi SA trades at $44.05 (market cap $104.83B), while SpaceX trades at $123.46 (market cap $1.58T). The key difference: SpaceX is far larger — about 15.1× Sanofi SA's market cap, and Sanofi SA pays a 5.5% dividend while SpaceX pays none. Which is the better fit depends on your goals.
| SNY | SPCX | |
|---|---|---|
Market Cap | $104.83B | $1.58T |
Sector | Health | Technology |
52-Week High | $52.34 | $202.09 |
52-Week Low | $41.33 | $119.85 |
Enterprise Value | $121.32B | $1.59T |
Dividend Yield | 5.5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SPCX trades at $119.85, down 3.34% today and 45% below its post-IPO high, with a bearish technical signal despite oversold RSI readings. The company reported Q1 2026 EPS of -$1.19, missing estimates by 260%, while revenue grew to $18.67B in 2025. SpaceX faces significant valuation concerns with a P/S of 84 and negative profitability metrics, though analyst consensus remains 100% buy-rated with a $237.78 price target representing 98% upside potential.
The stock presents high-risk/high-reward potential with strong institutional support but faces near-term headwinds from August lockup expirations and persistent losses. Long-term growth depends on Starlink expansion and AI contract wins, though current fundamentals don't justify the premium valuation. Investors must weigh analyst optimism against cash burn and execution risks in the competitive space sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About SpaceX
SpaceX is the world's leading aerospace manufacturer and launch provider. It designs and operates reusable rockets, spacecraft, and Starlink, a global satellite internet service with over 10 million subscribers across 160 countries.
Read more on SPCX →
